Review Article
The Effect and Safety of 5-HT1F Receptor Agonist Lasmiditan on Migraine: A Systematic Review and Meta-Analysis
Table 1
Characteristics of the included studies.
| | Included trials | Eligibility criteria | Intervention groups | Gender
Female/male () | Mean age (years) | White ethnic (%) | Migraines per month
Mean (SD) | Efficacy outcome | Adverse events |
| | Kuca et al., 2018 [23] | IHS 1.1 and 1.2.1 (3rd edition) | Placebo | 525/92 | 42.4 | 479 (77.6%) | 5.1 (1.8) | Headache pain-free; MBS free; | Dizziness; fatigue | | Lasmiditan 100 mg | 512/118 | 42.2 | 471 (74.8%) | 5.1 (1.8) | Sustained pain-freedom at 24 h/48 h; | Paresthesia; nausea | | Lasmiditan 200 mg | 515/94 | 41.4 | 450 (73.9%) | 5.3 (2.3) | Headache relief at 2 h; nausea/vomiting/phonophobia/photophobia-free at 2 h | Lethargy; somnolence | | Färkkilä et al., 2012 [22] | IHS 1.1 and 1.2.1 (2nd edition) | Placebo | 75/11 | 40.5 | 86 (100%) | 3.1 (1.7) | Headache response at 2 h | Dizziness; fatigue | | Lasmiditan 50 mg | 69/13 | 40.4 | 81 (99%) | 3.3 (1.6) | Pain-free at 2 h | Paresthesia; nausea | | Lasmiditan 100 mg | 68/14 | 42.0 | 81 (99%) | 3.3 (1.7) | Headache recurrence within 24 h | Vertigo | | Lasmiditan 200 mg | 65/6 | 39.5 | 70 (99%) | 3.3 (1.9) | Rescue drug 2-24 h; patient’s global | Sensation of heaviness | | Lasmiditan 400 mg | 65/5 | 38.7 | 69 (99%) | 3.1 (1.6) | Impression (much or very much better) at 2 h | Somnolence | | Ferrari et al., 2010 [21] | IHS 1.1 and 1.2.1 (2nd edition) | Placebo | 38/4 | 40.3 | 42 (100%) | 3.3 | Headache response at 2 h | Dizziness; fatigue | | Lasmiditan 20 mg (iv) | 24/4 | 38.9 | 28 (100%) | 3.3 | Pain-free at 2 h | Paresthesia | | Lasmiditan 30 mg (iv) | 14/2 | 40.3 | 16 (100%) | 3.5 | Sustained pain response | Sensation of heaviness | | Lasmiditan 45 mg (iv) | 3/1 | 40.8 | 4 (100%) | 2.8 | Sustained pain free; nausea/photophobia/phonophobia 2 h | Feeling of relaxation | | Goadsby et al., 2019 [24] | IHS 1.1 and 1.2.1 (3rd edition) | Placebo | 545/100 | 42.6 | 516 (80.0%) | 5.5 (2.4) | Headache pain-free at 2 h | Dizziness; fatigue | | Lasmiditan 50 mg | 554/100 | 42.8 | 524 (80.1%) | 5.2 (2.0) | MBS-free at 2 h | Paresthesia; nausea | | Lasmiditan 100 mg | 539/96 | 43.4 | 509 (80.2%) | 5.3 (1.9) | Sustained pain-free at 24 h | Somnolence | | Lasmiditan 200 mg | 536/113 | 41.8 | 522 (80.4%) | 5.3 (1.9) | Headache pain relief at 2 h; nausea/phonophobia/photophobia/vomiting free at 2 h | Lethargy |
|
|
IHS: International Headache Society; MBS: most bothersome symptom; SD: standard deviation; iv: injection of vein.
|
